At the recent BioStock Summit in Lund, Aixial’s experts, Ashley Hunter, Senior Director of Clinical Operations and Head of Strategic Development & Delivery, and Anna Yanaeva, Senior Director for Business Development, led an engaging discussion on the importance of “Utilising CROs for Effective Planning and Execution of Clinical Development”.
Clear communication is essential to drug development. At Aixial Group, our experienced medical writers know how to turn complex scientific data into clear, accurate documents. From regulatory protocols to scientific publications, they ensure clarity and compliance at every stage.
Digitalisation — Clinical trials are essential research studies evaluating medical intervention safety and efficacy, with varying designs and phases aimed at understanding treatment effects and patient experiences…
Pancreatic cancer is the 12th most common cancer in the world and remains one of the deadliest, with a five-year survival rate of only 13%, despite recent progress.
Breakthrough — Radiopharmaceutical therapy represents a novel approach to treating cancer, utilising radioactive atoms to target and destroy malignant cells with precision, without affecting the patient’s healthy tissues. A field in which Aixial has emerged as a pioneer.
Did you know that lung cancer is the most diagnosed cancer in the world? In 2022, it accounted for 12.4% of all new cancer cases and 18.7% of deaths. The 5-year survival rate for lung cancer has increased by 22% over the last 5 years due to advances in treatment. However, only 26% of cases are diagnosed at an early stage, when the survival rate is 61%.
Prostate cancer is on the increase globally, especially in men under the age of 50, and in 2022 there were 1.47 million new cases. The 5-year survival rate is close to 100%, largely thanks to advances in treatment and early detection.
Talents — The world of life sciences is vast and constantly evolving. It’s not enough to follow trends: you have to anticipate them, and to do that you need to bring together the best specialists. At Aixial Group, Stéphane Thérèse is well aware of this.
In recognition of Breast Cancer Awareness Month, Ashley Hunter, Head of Strategic Development and Delivery, offers valuable insights on the importance of early detection, the latest advancements and ongoing challenges in breast cancer research, and how Aixial Group is actively supporting the fight against breast cancer.
“We provide high-level expertise in a niche and critical area across the entire clinical supply chain flow, from the planning of the initial drug substance manufacturing to the Investigational Product reconciliation/destruction.”
“By ensuring that pharmaceutical products meet regulatory standards, I contribute to providing patients with access to safe and effective treatments for their medical conditions. This enhances the quality of life for individuals around the world.”
“Statistical consultant services are relevant in many places in the life science industry, we need evidence for everything in Life Sciences.”
